What exactly changed in the DCTH analyst rating on February 26, 2026?

BTIG maintained its **Buy** rating on Delcath Systems (DCTH) and lowered the price target to **$19** on February 26, 2026. The note preserves a positive view but reduces the valuation upside implied by the prior target.

How should investors use the DCTH analyst rating and new price target?

Use the DCTH analyst rating as one input: compare the **$19** price target to your entry price, assess company revenue guidance and HEPZATO uptake, and watch volume to confirm sentiment before altering positions.

Does the DCTH analyst rating from BTIG change Delcath’s long-term outlook?

BTIG’s maintained Buy keeps a constructive long-term view, but a lower price target signals more cautious near-term valuation. Long-term outlook depends on execution of commercial expansion and revenue milestones.

Where can I read the full analyst note and Delcath’s recent earnings details?

The BTIG note summary is reported on StreetInsider and Delcath’s Q4 2025 call transcript is on Seeking Alpha. See both sources for full context: [StreetInsider report](https://www.streetinsider.com/Analyst+Comments/Delcath+Systems+%28DCTH%29+PT+Lowered+to+%2419+at+BTIG/26067423.html) and [Earnings Q

Analyst Ratings

BTIG Maintains Buy on Delcath Systems (DCTH) Feb 2026, PT Cut to $19

ByDanny Kontos February 27, 2026February 27, 2026

BTIG maintained a Buy rating on Delcath Systems, Inc. (DCTH) on February 26, 2026, while lowering the price target to $19. The DCTH analyst rating update came at 11:54 AM and keeps BTIG bullish on Delcath’s therapeutic growth prospects despite a lower valuation. The firm recorded a price change since of 8.92% ($0.81) against a market cap of $312,300,000. This DCTH analyst rating note matters for investors watching pricing and near-term pathway catalysts for the company’s HEPZATO product.